Metabolic pathologies such as diabetes and obesity are associated with decreased level of circulating and bone marrow (BM)-derived endothelial progenitor cells (EPCs). It is known that activation of peroxisome proliferator-activated receptor alpha (PPARa) may stimulate cell differentiation. In addition, microparticles (MPs), small membrane vesicles produced by activated and apoptotic cells, are able to reprogram EPCs. Here, we evaluated the role of MPs carrying PPARa on both phenotype and function of progenitor cells from mice fed with a high-fat diet (HFD). HFD reduced circulating EPCs and, after 7 days of culture, BM-derived EPCs and monocytic progenitor cells from HFD-fed mice displayed impaired differentiation. At the same time, we show that MPs bearing PPARa, MPs PPARa1/1 , increased the differentiation of EPCs and monocytic progenitors from HFD-fed mice, whereas MPs taken from PPARa knockout mice (MPs PPARa-/-) had no effect on the differentiation of all types of progenitor cells. Furthermore, MPs PPARa1/1 increased the ability of progenitor cells to promote in vivo angiogenesis in mice fed with HFD. The in vitro and in vivo effects of MPs PPARa1/1 were abolished in presence of MK886, a specific inhibitor of PPARa. Collectively, these data highlight the ability of MPs carrying PPARa to restore the failed differentiation and functionality of BM-derived cells induced by HFD. STEM CELLS TRANSLATIONAL MEDICINE 2018;7:135-145 
INTRODUCTION
Metabolic syndrome is a complex disorder consisting of central obesity, hyperglycemia, hypertension, and hyperlipidemia [1] . In this pathology, increased blood glucose levels, insulin resistance, oxidative stress, dyslipidemia, and hypertension, compromise the vasculogenic ability to restore the endothelium, originating the vascular endothelium damage [2] . This is thought to be due, at least partially, to the dysfunction of bone marrow (BM)-derived endothelial progenitor cells (EPCs) biological activities and to the presence of proinflammatory state [3] . Interestingly, previous studies have demonstrated a link between reduced numbers and functionality of circulating EPCs and increased risk of cardiovascular diseases [4] , such as diabetes and metabolic syndrome [2] , but the mechanisms leading to the failed angiogenic function are not completely elucidated. It has been recognized that EPCs are an heterogeneous population and their cellular identity is classified according to their morphology, function, and growth potential. Stem cell antigen 1 (Sca1) and vascular endothelial growth factor receptor type 2 (Flk1) double positive cells have been considered as EPCs in the past. Increased levels of Sca1/Flk1 positive EPCs have been associated with improved reendothelialization in animal and clinical studies [5, 6] . Thus, one can advance the hypothesis that ex vivo expansion of EPCs might be a promising strategy to overcome the clinical problem of limited cell numbers in cardiovascular diseases. Microparticles (MPs) released from the plasma membrane blebs upon activation and/or apoptosis, can act as signaling elements in physiological or pathological conditions. Importantly, MPs can transfer receptors and organelles between cells and deliver mRNA and proteins into cells creating cell-cell interaction [7] . It is also demonstrated that MPs are able to program progenitor cells to repair tissue injury [8] .
Emerging evidence indicates that members of the peroxisome proliferator-activated receptor (PPAR) superfamily play a central role in the regulation of metabolic homeostasis and in cell differentiation. Among them, PPARa, implicated in lipid homeostasis and inflammation, represents a drug target for the treatment of some risk factors of metabolic syndrome [9] . Furthermore, PPARa regulates cardiac progenitor differentiation via NADPH oxidase [10] . We have shown that PPARa regulates EPC maturation and myeloid lineage differentiation through a NADPH oxidasedependent mechanism in mice [11] . In addition, we reported that PPARa carried by MPs stimulate cell differentiation through the Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) pathway in "healthy" mice [12] . However, it is not known whether MPs carrying PPARa (MPs PPARa1/1 ) affect BM-cell differentiation and the failed angiogenesis in the context of obesity. Thus, the aim of this study is to investigate the capacity of MPs PPARa1/1 to induce differentiation and neo-vascularization in an experimental model of obesity such mice fed with high-fat diet (HFD).
MATERIALS AND METHODS

Animal and Experimental Design
Male PPARa wild type (C57BL/6N, 8 weeks-old) mice were used in this study. They were maintained at 238C, conditioned to a 12 hours light/dark cycle. The animals were allowed free access to water and standard diet (SD) or HFD (37% Kcal from fat, 47.5% from carbohydrates, SAFE, Augy, France) for 12 weeks. Blood was obtained after 18 hours fasting period by cardiac exsanguinations under isoflurane-induced anesthesia, and plasma was collected and stored at 2808C until analysis. Tissues, including liver, adipose tissues and heart were removed, washed with phosphatebuffered saline (PBS), and weighed.
We also used homozygous PPARa-null mice on pure C57BL/6 background and corresponding wild-type for circulating MP isolation. PPARa knockout mice were generated by Pr. Frank Gonzalez (NIH, Bethesda, PPARa knockout mice MD) [13] .
All animal studies were carried out using approved institutional protocols (no. CEEA.2012.125) in accordance with Guide for the Care and Use of Laboratory Animals published by U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Circulating MP Isolation
Circulating MPs were isolated from venous blood obtained by cardiac puncture from wild type and corresponding PPARa knockout mice. Whole blood was centrifuged two times at 1,500g for 5 minutes at 208C to obtain platelet-free plasma (PFP). After circulating MPs were concentrated from PFP by two series of centrifugations at 16,000g for 45 minutes and resuspended in 0.9% saline salt solution and stored at 48C until subsequent use. MP quantification was performed using calibrated 10 mm-sized beads of known concentration on FC500 cytometer (Beckman Coulter, Villepinte, France). The physiological circulating concentration of MPs was used in all experiments as previously reported by Benameur et al. [12] .
Dot Blot Assay
Circulating MPs isolated from wild type or PPARa-deficient mice fed with SD were collected. Five micrograms of MPs were spotted onto nitrocellulose membrane. Membranes were then saturated at room temperature for 10 minutes in TBS-T (20 mM Tris base, 61.5 mM NaCl pH 7.8 and 0.1% Tween 20) buffer containing 5% bovine serum albumin (BSA). After washing, the membrane was incubated with the primary antibodies anti-PPARa (Santa Cruz Biotechnology Inc, Santa Cruz, CA) at room temperature for 1 hour. A secondary anti-rabbit antibody conjugated with horseradish peroxidase (Santa Cruz Biotechnology) was then added to the membrane. The protein-antibody complexes were detected by ImmunoCruz kit (Santa Cruz Biotechnology) according to the protocol of manufacturer. Blots were quantified by densitometry using Image J software.
Characterization of MP Phenotype
Membrane MP subpopulations of HFD-and normal-fed mice were discriminated in PFP according the expression of membranespecific antigens by flow cytometer. Phenotype of endothelial MPs was performed using anti-CD54 labeling, characterization of platelet, leukocyte, erythrocyte MPs, and MPs from progenitor cells was performed using anti-CD61, anti-CD45, anti-Ter-119/erythroid cell, and anti-CD133 labeling, respectively, (BioLegend, San Diego, CA). Also, Annexin V (BioVision Inc., Mountain View, CA) binding was used to numerate phosphatidylserine-expressing circulating MPs. Irrelevant mouse IgG was used as an isotypematched negative control for each sample.
Biochemical Analyses
Levels of glucose, triglycerides, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol in plasma were determined by spectrophotometry UV/visibleRoche/Hitachi Modular P (Roche Diagnostics, Mannheim, Germany) using enzyme-linked immunosorbent assay and Konelab/T Series) according to the protocol of the manufacturer. Serum insulin levels were measured by enzyme-linked immunosorbent assay (ELISA) kit (Mouse insulin Elisa kit, Millipore, Billerica, MA; ref: EZRMI-13K) following the manufacturer's instructions.
Isolation, Culture, and Characterization of BM-Derived Cells
Femurs and tibiae were dissected and carefully cleaned from adherent tissues. Then, the tips of each bone were removed and BM was collected by flushing out the content with DMEM (Lonza, Walkersville, MD). BM-derived cells were obtained by isolating mononuclear cells from BM of mice fed with normal chow and HFD using Histopaque H1083 (Sigma-Aldrich, St Louis, MO) density-gradient centrifugation, as previously described [11] [12] [13] [14] [15] [16] . Immediately after isolation, total mononuclear cells (10 6 cells/ cm 2 ) were plated on culture dishes coated with fibronectin (BD Biosciences, San Jose, CA, 10 mg/ml) and maintained in EGM-2 endothelial medium Bullet Kit system (Lonza, Walkersville, MD) supplemented with 5% fetal bovine serum. After 24 hours, nonadherent cells were removed by washing with PBS, and adherent cells were cultured in EGM-2 endothelial medium in the presence of circulating MPs from WT or PPARa-null mice and GW7647, specific PPARa agonist, (Santa Cruz Biotechnology, 1 mM), for the whole culture period of 7 days. In another set of experiments, PPARa inhibitor, MK886 (Santa Cruz Biotechnology, 20 mM) was preincubated with circulating MPs PPARa1/1 and MPs PPARa-/-for 1 hour, and then centrifuged and washed to eliminate excess of MK886, before to be added to BM-derived cells. Cell characterization was performed at day 0, immediately after isolation and after 7 days of culture. Three BM subpopulations were identified by flow cytometry using the following antibodies: EPCs (Sca1-PE/ Cy7-Flk1-PE), monocytes (Sca1-PE/Cy7-CD14-FITC), leukocytes (Sca1-PE/Cy7-CD45-PE/Cy5) (BioLegend).
After 7 days of treatment with MPs, adherent EPCs were analyzed by confocal microscopy and by flow cytometry. Adherent cells were incubated with 2.5 mg/ml 1, 19-dioctadecyl-3,3,39,39-tetramethyl-indocarbocyanine-labeled acetylated-LDL (Dil-Ac-LDL) (Harbor Bioproducts, Norwood, MA) for 2 hours and then, fixed with 2% paraformaldehyde and counterstained with 10 mg/ml FITC-labeled lectin from Bandeiraea simplicifolia (Sigma-Aldrich) for 1 hour at 378C. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Santa Cruz Biotechnology) at room temperature for 5 minutes. Double positive cells (DiIac-LDL 1 /FITC-lectin 1 ), identified as EPCs by confocal microscopy and by three independent investigators, were counted in five randomly selected high-magnification fields of each culture slide by using a computer-based program.
White Blood Cell Count
After 12 weeks of diet, peripheral blood specimens were obtained from tail of mice. A peripheral blood smear was made by placing a drop of blood on one end of the slides, and using a spreader slide to disperse the blood over the slides's length. Then, the slides were stained with May-Gr€ unwald-Giemsa (Sigma-Aldrich) to distinguish the various blood cells to be examined microscopically.
In Vivo Matrigel Plug Assay
After treatment, cells were detached and were mixed with 500 ll of Matrigel (ECMgel Sigma-Aldrich) with recombinant basic fibroblast growth factor (bFGF) (300 ng/ml, Peprotech, Rocky Hill, NJ). This mixture was injected subcutaneously on the back of male mice fed either with normal chow or HFD. One week after the initial injection, the Matrigel plug was removed, photographed, weighed, and homogenized in lysis buffer and incubated for 24 hours at 48C and then, disrupted with a Polytron (PRO250, PRO Scientific, Monroe, CT). Hemoglobin levels were determined using the Drakin method (Sigma-Aldrich) according to manufacturer's instructions.
PPARa Reporter Assays
The transcriptional activity of mouse PPARa was determined by measuring luciferase activity in PPARa reporter assays (Indigo Biosciences, State College, PA) according to the manufacturer's instructions. The reporter cells, derived from Chinese hamster ovary cells, constitutively express mouse hybrid PPARa, of which the DNA-binding domain (DBD) has been substituted with the DBD of GAL4, a transcription activator protein in yeast. These cells also incorporate a luciferase reporter gene driven by the GAL4 upstream activation sequence, which is the binding site for the DBD of GAL4. Thus, the effects of circulating MPs from WT or PPARa-null mice on the activation of PPARa can be determined by measuring the luciferase activity. Briefly, mouse PPARa reporter cells were dispensed into the wells of a 96-well assay plate and immediately treated for 24 hours with circulating MPs from WT or PPARa-null mice and with two selective PPARa agonists, GW7647 (1 mM), and serial dilution of GW590735. In another set of experiments, PPARa inhibitor, MK886 (20 mM) was preincubated with circulating MPs PPARa1/1 and MPs PPARa-/-for 1 hour, before to be added to reporter cells. At the end of the treatment, the medium was discarded and the luciferase detection reagent was added. Luminescence was measured using a Perkin Elmer Wallac 1420 Victor2 Multilabel Counter (Marshall Scientific, Hampton, NH).
Statistical Analysis
All data are represented as mean 6 SEM; n represents the number of mice. Significant differences between values in experimental and control group were calculated by Mann-Whitney U tests (nonparametric) using Prism software package 5.00 (GraphPAD Software, San Diego, CA). Differences were considered significant when p < .05.
RESULTS
High-Fat Diet Caused Metabolic Changes in Mice
Anatomical changes induced by HFD are shown in Supporting Information Table S1 . After 12 weeks, no significant difference in body weight was observed between mice fed either with normal chow or HFD, but consumption of HFD increased epididymal and visceral fat weight. In addition, HFD feeding significantly led to increased levels of total, HDL-and LDL-cholesterol, glucose and insulin when compared with mice fed with normal chow (Table 1) .
HFD Reduces Circulating MPs from Progenitor Cells
Flow cytometry analysis of circulating MPs (Supporting Information Fig. S1 ) showed that the total number of circulating MPs was not significantly different between HFD-and normal chow-fed mice indicating that HFD did not affect the circulating levels of MPs. Phenotypical characterization of cellular origin of MPs showed an increase of 2.6-fold and 2.8-fold of the circulating levels of platelet (CD41 1 ) and procoagulant (annexin V 1 ), respectively, as well as a reduction of MPs from progenitor cells (3.2-fold) in HFD-fed mice compared with normal chow-fed mice. Thus, these results demonstrate that HFD affect the cellular origins of MPs, in particular alters MP release from progenitor cells.
Circulating EPCs and In Vitro Cultured BM-Derived EPC Decline in HFD-Fed Mice
As expected, the number of Sca1/Flk1 positive EPCs in peripheral blood decreased in HFD-fed mice compared with those receiving (Fig. 1A, 1B) . These findings implicate that EPC mobilization from BM to circulation was markedly impaired in HFD-fed mouse model.
In previous studies, "early" EPCs were quantified by flow cytometry, and the most popular surface marker combinations comprise a heterogeneous composition of CD14 1 /CD45 1 positive cells, with hematopoietic and endothelial potential [14] . For this 
/Flk1
1 were identified as differentiating EPCs, Sca1 1 ) progenitors were identified by flow cytometry. At day 0, immediately after isolation, HFD had no effect on the all types of progenitor cells in both groups (Fig. 1C) . However, after 7 days of culture expansion, HFD reduced the subpopulation of EPCs and monocytic progenitor cells (Fig. 1D) . Since leukocytic progenitor population was not affected by HFD, we next decide to investigate whether HFD modules the function of EPCs and monocytic progenitors.
Changes in White Blood Cells Induced by HFD
To determine whether HFD can affect peripheral sites, blood was collected from two groups of mice. Analysis of complete blood counts revealed an increase in monocytes in mice fed with HFD (Table 2) . Overall, these results indicate that HFD-related changes occurring in the BM are also manifest in blood.
Effects of Circulating MPs
PPARa1/1 and MPs PPARa-/-on BM-Derived EPC Differentiation from HFD-Fed Mice As shown above, HFD feeding induced a reduction on expansion of EPCs from HFD-fed mice (see Fig. 1D ). Once verified that only MPs isolated from wild type (MPs PPARa1/1 ) expressed PPARa (Supporting Information Fig. S2 ), we assessed whether MPs carrying PPARa can favor in vitro EPC expansion. Circulating MPs isolated from wild type or PPARa-deficient mice were added to adherent BM-derived cells from normal-and HFD-fed mice for the whole culture period ( Fig. 2A, 2B ). After 7 days of culture, BMderived cells were characterized by the presence of endothelialspecific lectin BS-I binding [15] as well as double expression of Sca1 1 /Flk1 1 for differentiation analysis. By confocal microscopy, we found that cells from HFD-fed mice displayed a reduced DilAc-LDL/lectin labeling when compared with mice fed with normal chow ( Fig. 2A, 2B (Fig. 2B) . These results were confirmed by flow cytometry (Fig. 2C, 2D ). In addition, the specific PPARa agonist GW7647 induced similar effects of MPs PPARa1/1 . To test whether the MPs effects are primarily mediated by PPARa carried by MPs, we preincubated MPs isolated from WT or PPARa-null mice with PPARa antagonist (MK886, 20 mM) (Fig. 2C, 2D) . Interestingly, the preincubation of MPs PPARa1/1 with MK886 abolished the effects of MPs PPARa1/1 on EPC differentiation in both groups of mice (Fig. 2D) . In contrast, MK886 treatment appeared to reduce Sca1 1 /Flk1 1 expansion induced by MPs PPARa-/-of BM-derived cells from normal-fed mice, but not from HFD-fed mice. These results suggest that PPARa is essential for the effects of MPs on EPC maturation from HFD-fed mice.
Effects of MPs on Differentiation of Monocytic Progenitor Cells from HFD-Fed Mice
Since HFD affects the differentiation of hematopoietic lineage toward monocytic cells [16] , we investigate whether circulating MPs isolated from WT or PPARa-deficient mice are able to restore, in vitro, this impairment. Unfractionated BM-derived cells were cultured in the absence or in the presence of MPs PPARa1/1 or MPs PPARa-/-for 7 days, and then, analyzed by flow cytometry. We found that, after 7 days of culture, GW7647 and MPs PPARa1/1 were able to increase the differentiation of monocytic progenitors from either normal-or HFD-fed mice, respectively, (Fig. 3A, 3B ). In contrast, MPs PPARa-/-had no effect on the differentiation of monocytic progenitor cells under the same experimental conditions (Fig. 3B) , suggesting that the presence of PPARa is necessary for MPs to develop monocytic differentiation. In addition, no significant effect was observed on leukocyte progenitor cells regardless of diet (data not shown).
Next, to assess whether MPs carrying PPARa are implicated in hematopoietic progenitor cell differentiation, we cultured for 7 days BM-derived cells with MPs pre-treated with MK886. As shown in Figure 3A and 3B, MK886 treatment prevented the effects of MPs PPARa1/1 on BM-derived cells from the two groups of mice. Moreover, BM-derived cells either from normal-or HFDfed mice treated with MPs PPARa-/-alone or in the presence of MK886 did not modify monocytic differentiation.
Together these data suggest that in mice with early metabolic alterations monocytic differentiation is rescued by MPs carrying PPARa.
In Vivo Modulation of Angiogenic Properties of BM-Derived EPCs by MPs
We further characterized the angiogenic ability of MPs by Matrigel plugs subcutaneously injected into normal-and HFD-fed mice. After 7 days, mice were sacrificed, and blood vessel growth into the gels was quantified by measuring hemoglobin content of the plugs, as shown in Figure 4A .
Prior, we addressed whether the HFD induced functional alterations in BM-derived cells. As expected, hemoglobin content in plugs from HFD-fed mice was significantly reduced when compared with that of plugs from mice fed with normal chow (Fig. 4A,  4B ). These results indicate that the function of BM-derived EPCs from HFD mice was reduced and was associated with defects of their ability to promote neoangiogenesis.
Next, similar experiments were performed in the presence of either GW7647 or MPs PPARa1/1 . As shown in Figure 4A , vascularization of the plugs was significantly stimulated when BM-derived cells were pretreated with GW7647 (1 mM) or with MPs PPARa1/1 , but not with MPs PPARa-/-, suggesting a key role of PPARa in the effects evoked by MPs (Fig. 4A, 4B) .
To confirm these results, we inhibited PPARa harbored by MPs using MK886 for in vivo angiogenesis study. As observed in Figure 4A , the degree of vascularization was lower in the MPs PPARa1/1 -MK886 treated plugs from normal-and HFD-fed mice than in those treated with MPs PPARa1/1 . In addition, when 
Effects of Circulating MPs
PPARa1/1 on the Activation of Mouse PPARa
Here, the manifold effects of circulating MPs PPARa1/1 suggest an underlying mechanism, similar to the activities of PPARa agonists such as fibrates. Therefore, the effects of circulating MPs isolated from WT or PPARa-deficient mice on the activation of mouse PPARa were investigated using the previously described reporter assays. Upon binding to an agonist, the PPAR-GAL4 fusion protein activates a luciferase reporter. As shown in Figure 5B , a significant increase in PPAR nuclear signaling was observed with 1 mM of selective PPARa agonist, GW7647, when compared with control. Remarkably, circulating MPs PPARa1/1 , but not MPs PPARa-/-, increased the basal luciferase activity by 12.7-fold corresponding to 281 nM of the specific and potent PPARa activator GW590735, with an EC 50 of 124 nM (Fig. 5A, 5B) . In contrast, this activity was inhibited by the preincubation of MPs These findings indicate that MPs PPARa1/1 have the ability to reinforce PPARa activation as much as the specific and potent PPARa agonist.
DISCUSSION
Herein, we demonstrate that metabolic dysfunctions altered BMderived progenitor cells differentiation and functionality in mice. The BM is a highly vascularized tissue and contributes to the transport of BM-derived cells to the systemic circulation. In the present study, the HFD-fed mouse model has been used as a robust model to study the development of impaired functions of BM induced by metabolic dysfunction [17, 18] . HFD feeding did not modify total body weight of mice after 12 weeks of treatment, but it significantly increased adiposity, total cholesterol and glucose levels and reduced the ratio HDL/LDL compared with mice fed with a normal chow diet. These results underscore an "early stage of diet-induced obesity." This is in agreement with our previous report showing that, in the same model, HFD-induced metabolic alterations without affecting body weight [16] .
Importantly, similar to human studies [19] , we found that the EPC mobilization ability from BM to circulation is curtailed in HFDfed animals. In agreement with the results obtained by flow cytometry analysis, HFD significantly reduced circulating MPs from progenitor cells. Consistent with this notion, it has been proposed that impaired phosphorylation of BM endothelial NO synthase leads to reduced mobilization of BM-derived EPCs into the circulation of diabetic mice [20] . We cannot rule out the possibility that EPCs from HFD-fed mice display a reduced half-life in circulation. We showed both reduced numbers of these precursors in blood and impaired in vitro differentiation of BM-derived progenitor cells. Furthermore, after 7 days of culture, also BM-derived monocytes from HFD-fed mice are reduced, but unlike of EPCs, we observed an increase of circulating mature monocytes. One potential explication could be that blood sample analysis of circulating monocytes does not necessarily represent their mobilization from the BM but also from other niches such as liver or spleen. Hence, HFD appears to cause dysregulation to more primitive hematopoietic progenitor cells in BM. Our data are in agreement with those of Luo et al. [21] showing that obesity significantly alters hematopoietic and lymphopoietic function in BM, suggesting substantial changes in this primary tissue.
Metabolic diseases such as diabetes and obesity are associated with alterations in angiogenesis. Patients with these diseases display impairment of reendothelialization after vascular injury, associated not only with the reduction of number of EPCs but also with alterations of their functions [22, 23] . Several strategies are designed to improve EPC function in these patients, such as the use of statins [24] and PPARg agonists [25] , and the ex vivo genetic modifications of EPCs [22, 26] . We have also shown that in vitro treatment with low concentrations of ethanol can improve the functionality of EPCs from HFD-fed mice [16] suggesting that in vitro manipulation may be considered as a therapeutic tool regarding expansion and angiogenic properties of BM-derived cells. In this respect, it has been recently shown that MPs, small vesicles released by cells, can be potential therapeutic tools in pathologies associated with endothelium injury by inducing recruitment of EPCs in the sites of the vascular lesion. Indeed, treatments with endothelial-and platelet-derived MPs participate in the development of blood vessels or angiogenesis [8, 27] . For instance, the endothelial characteristics of "early EPCs" may also be acquired due to uptake of platelet MPs, as a simple transfer of antigens CD31 and vWF [28] . But, few studies have analyzed the effects of total circulating MPs on angiogenesis [7] . It has been reported that circulating MPs, regardless of their sources, participate in vessel remodeling following endothelial denudation [29] .
In previous work, we have shown that circulating MPs harboring PPARa seem to be essential the proangiogenic reprogramming of EPCs. Since in the present study, differentiation of BM-derived EPCs and monocytes were significantly decreased by HFD, we studied the ability of MPs to restore them. We examined the behavior of these putative vascular progenitors because it is known that CD14 1 cell populations may contain cells that can give rise to EPCs or be recruited to the site of neovascularization and directly contribute to angiogenesis [30, 31] .
Here, we show that MPs PPARa1/1 favor EPC and monocytic differentiation in BM-derived cells from mice normal-and HFDfed mice. Interestingly, incubation of MPs with the PPARa antagonist, MK886 prevented the effects induced by MPs PPARa1/1 , suggesting that the presence of PPARa in MPs is necessary to reestablish EPC and CD14
1 cell differentiation in HFD-fed mice. Surprisingly, MK886 treatment appeared also to prevent EPC differentiation induced by MPs PPARa-/-in BM-derived cells from normal fed-mice, suggesting that its mechanism of action may extend beyond a specific nuclear receptor. Indeed, it is thought to prevent the conformational change in PPARa required to dismiss corepressors and recruit coactivators for gene transcription [32] . Structural features of this shift are common to members of the nuclear receptor superfamily [33] and it is possible that MK886 blocks multiple nuclear receptors implicated in EPC differentiation. These data are in accordance with those reported by Kehrer et al. [32] showing that MK886 inhibits PPARa and, though less effectively, either PPARb or PPARg.
In contrast to the results of Benameur et al.
[12], we observed that also MPs PPARa-/-affected EPC expansion in normal-fed mice. One possible explication for this discrepancy might relate to the differences in mouse age (8 weeks old vs. 20 weeks in the present study). Indeed, mature BM-derived cells might respond differently to MPs PPARa-/-than progenitors from young mice. According to the aforementioned data, the proangiogenic property of these MPs into Matrigel plugs was correlated, at least in part, with expression of EPC differentiation markers. Indeed, we demonstrate that isolated BM-derived cells from normal-and HFD-fed mice expanded by in vitro MPs PPARa1/1 treatment are able to generate in vivo functional vessels. Conversely, in mice fed with normal chow, we found that MPs PPARa-/-treatment increased EPC differentiation, despite no change on the hemoglobin content in Matrigel plug. Several explanations can be advanced. Thus, it is possible that MPs PPARa-/--treated EPCs are not functional or even they form nonfunctional vessels. This finding indicates that MPs carrying PPARa play an essential role in neovascularization.
Despite the fact that all the above-described pleiotropic effects of MPs are specifically related to the activation of the PPARa pathway, the molecular mechanism by which MPs PPARa1/1 could affect BM niche and the development of progenitor cells is not yet clear. As previously shown by Benameur et al. [12] , PPARa expession is not transferred into BMderived cells after MPs PPARa1/1 treatment although it is expressed and functional in BM-derived cells. In this work, we demonstrate that MPs PPARa1/1 activate PPARa using a reporter cell line over expressing GAL4 fusion proteins to DBD of PPARa, suggesting they serve as a natural ligand. Regardless of the exact nature of the interaction, it is possible that lipids, protein carried by MPs PPARa1/1 may act as the endogenous ligands leading to modification of BM-derived cell phenotype. In this context, the presence of PPARa within the MPs might induce through a nongenomic mechanism protein and pi tlblipid O c 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by modification or direct protein/protein binding with key signaling pathways. Indeed, it is possible that PPARa, characterized as a "transcription factor," has also nontranscriptional functions [34] . For example, it has been described that PPARa may regulate neuronal nicotinic acetylcholine receptor function by a nongenomic stimulation of tyrosine kinases [35] . Furthermore, it was demonstrated that PPARa and AP-1 or NF-jB can functionally interact by interfering with signaling pathways (such as protein phosphorylation), and this modulates transcription factor activity [36] . Thus, further studies are needed for a better understanding of the mechanism evoked by MPs PPARa1/1 on BMderived progenitor cells in vitro, and on in vivo in order to elaborate an efficient strategy for their potential application to correct failed angiogenesis in obesity or diabetes.
A limitation of our study is the lack of MP characterization, a longer time course of analysis may be necessary to evaluate their components. For this reason, we cannot exactly assess how PPARa carried by MPs is implicated in BM-derived cells differentiation pathway. Here, we demonstrated that this process is likely to be regulated by crosstalk between PPARa and his surrounding microenvironment in MPs. For instance, a mechanism by which PPARa exerts EPC differentiation might be through modulating lipid levels. Indeed, it is well known that lipids, and especially lipoproteins can act on the target cells via MPs inducing phenotypic and functional changes in the recipient cells [37] . In this connection, PPARa deletion could influence the compositions of both external and internal membranes of MPs from PPARa-null mice. Indeed, it was reported that basal fatty acid homeostasis in PPARa-null mice is altered, that is, abnormal accumulation of lipid in the liver, lower serum triglycerides and altered constitutive expression of fatty acid-metabolizing enzymes [38] . These alterations might well be related.
CONCLUSION
Overall, these data support that HFD-related changes impair EPC mobilization from BM to circulation and alters the stem cell niche, independently of obesity development. In addition, in HFD-fed mice, MPs carrying PPARa restore differentiation of hematopoietic cells and their recruitment into target sites for new blood vessel formation without typical drug associated side effects. These insights will open new possibilities to impact BM-derived cells function by MPs carrying PPARa. In this respect, MPs carrying PPARa can represent a true therapeutic potential tool on pathophysiological conditions associated with failed EPC differentiation such as diabetes, although the mechanisms involved in these effects are not completely elucidated. However, the fact that circulating MPs are from diverse cell origins may lead to heterogeneous or multipledirectional effects of MPs. Further studies are needed to completely understand the effects of MPs carrying PPARa on progenitor differentiation during HFD conditions in which BM microenvironment and, in consequence, BM niche function is altered.
